PABPN1 and oculopharyngeal muscular dystrophy: Valproic acid, a direct inhibitor of histone deacetylase classes I and II, could ameliorate the mutant PABPN1 toxicity in cellular and worm models of OPMD by enhancing the level of histone acetylation [63].